Clinical Trial Update: Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

View source ↗

Summary

An observational study evaluating Rebismart 2.0 plus MSdialog in relapsing-remitting multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• MSdialog
• Rebismart 2.0

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-remitting | Status: TERMINATED